M. Jarema

Publications20
h-index7
Citations359
Highly Influential Citations14
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • K. Domschke
  • 332 Publications, 9,402 Citations
  • J. Deckert
  • 313 Publications, 9,040 Citations
  • D. Nutt
  • 706 Publications, 26,340 Citations
  • P. Zwanzger
  • 261 Publications, 7,474 Citations
  • Publications
  • Influence
Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition
Abstract Objective: Biomarkers are defined as anatomical, biochemical or physiological traits that are specific to certain disorders or syndromes. The objective of this paper is to summarise the… Expand
  • 97
  • 4
  • PDF
Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics
Abstract Objectives: Biomarkers are defined as anatomical, biochemical or physiological traits that are specific to certain disorders or syndromes. The objective of this paper is to summarise the… Expand
  • 75
  • 3
  • PDF
Fighting stigma of mental illness in midsize European countries
PurposeStigma is the most powerful obstacle to the development of mental health care. Numerous activities aiming to reduce the stigma of mental illness and the consequent negative discrimination of… Expand
  • 56
  • 3
  • PDF
Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone.
Metabolic disturbances are a growing concern for the treatment of schizophrenia. As decreased activity and poor sleep quality are risk factors for metabolic disturbances, we investigated the activity… Expand
  • 56
  • 2
Stigmatization of psychiatrists and general practitioners: results of an international survey
Abstract The stigma of mental illness affects psychiatry as a medical profession and psychiatrists. The present study aimed to compare the extent and correlation patterns of perceived stigma in… Expand
  • 36
  • 1
Trazodon - lek przeciwdepresyjny: mechanizm działania i miejsce w leczeniu depresji
  • 4
  • 1
Daytime sleepiness and EEG abnormalities in patients treated with second generation antipsychotic agents.
BACKGROUND The aim of this study was to verify whether or not an increased prevalence of excessive daytime sleepiness (EDS) or EEG abnormalities is observed in patients with schizophrenia spectrum… Expand
  • 7
Nonpharmacological Interventions for the Treatment of Cardiometabolic Risk Factors in People With Schizophrenia—A Systematic Review
Background: People suffering from schizophrenia are notably vulnerable to cardiometabolic risk factors (CMRF), such as obesity, high blood pressure, hyperglycemia and insulin resistance, high serum… Expand
  • 8
  • PDF
[Oxytocin model of formation of psychotic symptoms and its implications for research on oxytocinergic pathway in schizophrenia].
There are more and more data to support the dysregulation of the oxytocinergic pathway in schizophrenia. The development of the above branch of knowledge began to evolve alongside the mainstream of… Expand
  • 3
  • PDF
DEPRESSIVE SYMPTOMS IN THE FIRST EPISODE OF SCHIZOPHRENIA – ANALYSIS OF POLISH RESULTS OF THE EUFEST STUDY
  • 3